ACI-19764
AssetSmall molecule
Inhibits NLRP3 inflammasome activation to reduce downstream inflammatory cytokine release.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- NLRP3
- Indications
- 3
- Trials
- 1
- Developers
- 1
Indications
3Cardiovascular risk
Phase 1ir.acimmune.com7 Oct 2026
Obesity
Phase 1RECRUITINGNCT07463196clinicaltrials.gov7 Oct 2026
Type 2 diabetes
Phase 1RECRUITINGNCT07463196clinicaltrials.gov7 Oct 2026
- Targets and what it contains3
- Owner and partners2
- Trials1
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 2 sources